Article
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
Blood advances - 12 May 2020
Gardin Claude, Pautas Cécile, Fournier Elise, Itzykson Raphaël, Lemasle Emilie, Bourhis Jean-Henri, Adès Lionel, Marolleau Jean-Pierre, Malfuson Jean-Valère, Gastaud Lauris, Raffoux Emmanuel, Lambert Juliette, Braun Thorsten, Thomas Xavier, Chantepie Sylvain, Cluzeau Thomas, de Botton Stéphane, Berthon Céline, Boissel Nicolas, Duployez Nicolas, Terré Christine, Peffault de Latour Régis, Michallet Mauricette, Celli-Lebras Karine, Preudhomme Claude, Dombret Hervé
Abstract excerpt
In this study, we aimed to refine prognostication of older with acute myeloid leukemia (AML) after intensive chemotherapy. Five hundred and nine patients aged 60 years or older (median age, 68 years) were prospectively enrolled in the intensive Acute Leukemia French Association (ALFA)-1200 trial between 2012 and 2016, and 471 patient samples were submitted to multigene analysis. Mutations in any of 8 genes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.